Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market

Trading Expected to Begin on October 10, 2019

NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMDD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company's common stock has been approved for listing on The Nasdaq Capital Market. Trading on Nasdaq is expected to begin on Thursday, October 10, under the existing symbol, "RLMD." 

Relmada Therapeutics Corporate Logo

"The listing of our stock on The Nasdaq Capital Market represents a substantial milestone for our company," said Sergio Traversa, CEO of Relmada Therapeutics. "This uplisting has the potential to augment our visibility within the investment community, increase the liquidity of our stock, broaden our shareholder base, and enhance long-term shareholder value. I would like to extend special thanks to the Relmada management and legal teams for making Relmada a member of this prestigious, and globally trusted exchange, an especially important event in anticipation of the Phase 2 clinical study results expected later this quarter."

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. For more information, please visit Relmada's website at

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Investor Contact 
Brian Ritchie
LifeSci Advisors
T. 212.915.2578

Cision View original content to download multimedia:

SOURCE Relmada Therapeutics, Inc.